# Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

> **NCT04470622** · PHASE2 · TERMINATED · sponsor: **Heron Therapeutics** · enrollment: 27 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Aprepitant injectable emulsion
- **DRUG:** Saline Placebo

## Key facts

- **NCT ID:** NCT04470622
- **Lead sponsor:** Heron Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-20
- **Primary completion:** 2021-04-09
- **Final completion:** 2021-06-03
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Study was terminated early by Heron, and was not terminated for safety reasons.
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04470622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04470622, "Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04470622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*